

# BIOSPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	20-Jul-2023	20-Jul-2026	: Date of Next Review
Prepared By:	Virginia Pena	BSI-COA-0185v.1.1	: Supersedes
QA/QC Approval:	Carissa Albert	Dora Meissner	: Management Approval
Reason for Revision:	See Revision History in MasterControl.		

## CERTIFICATE OF ANALYSIS

### DEXTRAN SULFATE SODIUM SALT, 8000MW

### BIO PHARMA GRADE / DXSE-4250-05

### LOT: DXSE-0123-00022

(C<sub>6</sub>H<sub>7</sub>Na<sub>3</sub>O<sub>14</sub>S<sub>3</sub>)<sub>n</sub> \* M.W. 8000 \* CAS# 9011-18-1  
 Manufacture Date: 10/16/23 Retest Date: 06/30/25  
 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013  
 Packaging Date: 11/06/23  
 Packaging Site: 100 Majestic Way, Bangor PA, 18013

ANALYSIS	SPECIFICATION	TEST RESULT
Appearance	Off white to light yellow powder	Off white to light yellow powder
Clarity (20% solution) Absorbance at 360nm	≤ 0.9 OD unit	< 0.9 OD unit
Chloride	≤ 1000 ppm	< 1000 ppm
Endotoxin	≤ 0.012EU/mg	< 0.005 EU/mg
Free Sulfate	≤ 0.2%	< 0.2%
Glucose	35 - 48%	37%
Identification (Colorimetric)	Passes Test	Passes Test
Insoluble Iron	≤ 2%	0.00045%
Loss on Drying	≤ 10%	4%
Manganese (as reported)	≤ 1 ppm	0.066 ppm
pH (1% solution)	5.0 - 7.5	7.0
Residue on Ignition	35 - 50%	42%
Pyridine	≤ 2%	< 2%
Specific Rotation [α] <sub>D</sub> <sup>20</sup>	+75° - +105°	+84°
Specific Viscosity (In 1.0M NaCl at 25°C)	0.018 - 0.032	0.029
Total Bioburden	≤ 100 CFU/g	< 10 CFU/g
Sulfur	17 - 20%	19 %

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: BSI-ATM-0091

INTENDED USE: Once the Validation Study is complete, Material represented by this Certificate of Analysis is suitable for use as a process chemical. It is manufactured in accordance with the IPEC-PQG Joint Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug, Drug Product or Household Item.

SHELF LIFE: The retest date is assigned based on the industry standard for Dextran Sulfate Sodium Salt 8000MW. BioSpectra's Stability Testing Program is ongoing to further support the retest date.

Prepared by: Amil McCall Date: 11/8/24 Job Title: QA Tech III

Reviewed by: Carli Hunt Date: 11/8/24 Job Title: Senior Quality Manager